Dendritic cell-based tumor vaccine for cervical cancer I: In vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 9, 2003, Pages 511-520

  Nonn, Marion ^a   Schinz, Manuela ^a   Zumbach, Klaus ^b   Pawlita, Michael ^b   Schneider, Achim ^a   Dürst, Matthias ^a   Kaufmann, Andreas M ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cytotoxic T cell; Immunotherapy; T cell response; Tumor infiltrating lymphocytes; Uterine cancer

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; ONCOPROTEIN; RECOMBINANT ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS E7 ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELL SPECIFICITY; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME IMMUNOASSAY; HAPLOTYPE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL LINE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; UTERINE CERVIX CANCER; WART VIRUS;

CANCER VACCINES; CLONING, MOLECULAR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MONOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PULSE THERAPY, DRUG; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0141484489     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0462-6     Document Type: Article

References (53)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796-802
2. Braspenning J, Manetti R, Zumbach K, Meschede W, Gissmann L, Tommasino M (1997) A general purification protocol for E7 proteins from "high- and low-risk" human papillomavirus types expressed in the yeast Schizosaccharomyces pombe. Protein Expr Purif 10:192-201
3. Brinton LA (1992) Epidemiology of cervical cancer-overview. IARC Sci Publ 119:3-23
4. Castellanos MR, Hayes RL, Maiman MA (2001) Synthetic peptides induce a cytotoxic response against human papillomavirus type-18. Gynecol Oncol 82:77-83
5. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. (1991) Human papillomavirus 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 88:110-114
6. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, Taylor-Robinson D, Stanley MA (1994) Immunological events in regressing genital warts. Am J Clin Pathol 102:768-774
7. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R, Melief CJ (1998) Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16- induced tumor cells. Cancer Res 58:724-731
8. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R (2002) Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62:472-479
9. Evans EM, Man S, Evans AS, Borysiewicz LK (1997) Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 57:2943-2950
10. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJM, Kast WM (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242-2249
11. Friedl J, Stift A, Paolini P, Roth E, Steger GG, Mader R, Jakesz R, Gnant MF (2000) Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer. Cancer Biother Radiopharm 15:477-486
12. Ho GY, Burk RD, Fleming I, Klein RS (1994) Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer 56:788-792
13. Honma S, Tsukada S, Honda S, Nakamura M, Takakuwa K, Maruhashi S, Kodama S, Konazawa K, Takahashi T, Tanaka K (1994) Biological-clinical significance of selective loss of HLA-class I allelic product expression in squamous-cell carcinoma of the uterine cervix. Int J Cancer 57:650-655
14. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer C J, Walboomers JM (1997) A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35:791-795
15. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135-3142
16. Kather A, Ferrara A, Nonn M, Schinz M, Nieland J, Schneider A, Dürst M, Kaufmann AM (2003) Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination. Int J Cancer 104:345-353
17. Kaufmann AM, Gissmann L, Schreckenberger C, Qiao L (1997) Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens. Cancer Gene Ther4:377-382
18. Kaufmann AM, Gissmann I, Simms P, Schreckenberger C, Qiao L (2000) Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells. Immunobiol 202:339-352
19. Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H, Muller RT, Jochmus I, Gissmann L, Schneider A, Durst M (2001) HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 92:285-293
20. Liu Y, Chiriva-Internati M, Grizzi F, Salati E, Roman J J, Lira S, Hermonat PL (2001) Rapid induction of cytotoxic T cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther 8:948-957
21. Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, Gissmann L, Pawlita M (1998) Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 36:475-480
22. Michel N, Öhlschläger P, Osen W, Freyschmidt EJ, Guthörlein H, Kaufmann A, Müller M, Gissmann L (2002) T cell response against human papillomavirus (HPV) 16 E7 in mice: comparison of Cr-release assay, intracellular IFN-γ production, ELISPOT and tetramer staining. Intervirology 45:290-299
23. Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A (1999) Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 5:445-454
24. Munderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast MW, Fascio G, Marty V, Weber J (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Canc Res 6:3406-3416
25. Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA (1999) Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 59:1184-1187
26. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332
27. Nikoloff B, Turka L (1994) Immunological functions of nonprofessional antigen-presenting cells: new insights from studies of T-cell interaction with keratinocytes. Immunol Today 15:464-469
28. Nindl I, Lotz B, Kuhne-Heid R, Endisch U, Schneider A (1999) Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay. J Clin Pathol 52:17-22
29. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM (1995) Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 18:86-94
30. Petry KU, Scheffel D, Bode U, Gabrysiak T, Kochel H, Kupsch E, Glaubitz M, Niesert S, Kuhnle H, Schedel I (1994) Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 57:836-840
31. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJM, Kast WM (1995) Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934-5943
32. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Cells E, Grey H, Trimbos B J, Kast WM, Melief CJ (2000) Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23:255-266
33. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S (1999) Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1:362-368
34. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93
35. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196:137-151
36. Rudolf MP, Man S, Melief CJ, Sette A, Kast WM (2001) Human T cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res 7:788s-795s
37. Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182:389-400
38. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ (1999) Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 73:5402-5410
39. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jayaprabhu S, Pecorelli S, Parham GP, Cannon MJ (2001) Expression of CD56 by human papillomavirus E7-specific CDS+ cytotoxic T tymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clin Cancer Res 7:804s-810s
40. Schuler G, Steinman RM (1997) Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186:1183-1187
41. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296
42. Stoler M, Rhodes C, Whitbeck A, Wolinsky S, Chow L, Brocker T (1992) Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 23:117-128
43. Sulitzeanu D (1993) Immunosuppressive factors in human cancer. Adv Cancer Res 60:247-267
44. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223:1-15
45. Tuting T, DeLeo AB, Lotze MT, Storkus WJ (1997) Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 27:2702-2707
46. von Knebel-Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L (1988) Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 48:3780-3786
47. von Knebel-Doeberitz M, Rittmuller C, zur Hausen H, Durst M (1992) Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 51:831-834
48. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 89:12-19
49. Welters MJP, de Jong A, van den Enden SJF, van der Hulst JP, Kwappenberg KMC, Hassane S, Franken KLMC, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJM, Offringa R, van der Burg SH (2003) Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63:636-641
50. Williams OM, Hart KW, Wang EC, Gelder CM (2002) Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. J Virol 76:7418-7429
51. Wollscheid V, Kuhne-Heid R, Stein I, Jansen L, Kollner S, Schneider A, Durst M (2002) Identification of a new proliferation-associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomas. Int J Cancer 99:771-775
52. Youde S, McCarthy C, Dunbar R, Cerundolo V, Borysiewicz LK, Man S (2000) Cross-typic specificity of human HPV16 E7 specific CTL lines and the relationship to TCR affinity. 18th International Papillomavirus Conference, 2000, Barcelona, Spain
53. zur Hausen H (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9-13